Rigel Pharmaceuticals
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
611 Gateway Blvd Ste 900, South San Fran...Phone Number
(800) 332-1088Website
www.tavalisse.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing, and providing novel small-molecule drugs that improve the lives of patients with immune-mediated disorders in hematology, oncology, and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. TAVALISSE is Rigel's first FDA-approved product.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rigel Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Rigel Pharmaceuticals recently announced quarterly report
Click to see if Rigel Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Rigel Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Rigel Pharmaceuticals has new funding data
Check out if Rigel Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Rigel Pharmaceuticals launches new products
Rigel Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Rigel Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Rigel Pharmaceuticals
Find more new buyers
Compare Similar Companies to Rigel Pharmaceuticals
Compare insights from companies similar to Rigel Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Company Profile Activity
Activity Insights
Rigel Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Rigel Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Rigel Pharmaceuticals.
Rigel Pharmaceuticals Tech Stack
Rigel Pharmaceuticals News & Media
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil
MONTREAL, May 08, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., received regulatory approval from ANVISA for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1Rigel Reports First Quarter 2025 Financial Results and Provides Business Update
First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025 R289 granted Orphan Drug designation for the...Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
SOUTH SAN FRANCISCO, Calif., March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. (collectively "Annora") resolving patent...Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico
MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., received regulatory approval from COFEPRIS for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Rigel Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing, and providing novel small-molecule drugs that improve the lives of patients with immune-mediated disorders in hematology, oncology, and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. TAVALI... Read More
